At Melanoma Institute Australia every clinician is also a researcher. Their efforts are multiplied by the corps of dedicated researchers across several campuses. The management team and board look after the institute’s business functions, managing the clinical trials, the BioSpecimen Bank and research information. You can read a bit about all of them here.
- The Poche Centre
- Concord Repatriation General Hospital
- Kolling Institute of Medical Research
- Lake Macquarie Private Hospital
- Macquarie University
- Nowra Outpatient Clinics
- QIMR Berghofer Medical Research Institute
- Royal North Shore Hospital
- Royal Prince Alfred Hospital
- Skin and Cancer Foundation Australia
- Strathfield Private Hospital
- St Vincents and Mater Health
- Sydney Adventist Hospital
- Sydney Day Surgery
- The University of Sydney
- The University of Newcastle
- Westmead Hospital
- Westmead Millennium Institute for Medical Research
Carole Renouf - MA Hons, Dip Ed, MAICD
Carole Renouf was appointed as the inaugural Chief Executive Officer of MIA in 2016. Carole has dedicated most of her career to the not-for-profit sector, specialising initially in health education, consumer advocacy, marketing, communications and fundraising before transitioning to senior executive management and leadership roles. Some of the organisations Carole has worked for include NSW Health, the Consumers’ Association (CHOICE), WWF Australia and UNSW. She was CEO of Garvan Research Foundation 2005-2010 and this was the beginning of her reputation with major gifts to medical research. During her tenure, the Foundation’s annual revenue increased from $2.5 million to $15 million and Carole also ran the capital campaign to raise $40 million in philanthropy to build the Kinghorn Cancer Centre. Carole was CEO of the National Breast Cancer Foundation (NBCF) 2011-2015, successfully raising its profile, fundraising revenue and research grant disbursements so that NBCF became ranked as the fourth most respected charity in Australia. Prior to taking up her position at MIA, Carole spent a year leading the capital campaign for redevelopment of St Vincent’s Private Hospital Sydney, raising $27.5 million.
Reg Richardson - AM FCPA FCIS ACSA Dip CM
Reg Richardson was appointed the Chairman of the Melanoma Institute Australia in 2007. Throughout his career he has owned and managed diverse businesses predominantly involved in service industries. Reg is involved with a number of philanthropic organisations including Melanoma Institute Australia, Friends of the Mater Foundation, and the Poche Centre of Indigenous Health at the University of Sydney, Flinders University, Melbourne University and University of Western Australia. Previously, Reg has served on the boards of the Museum of Contemporary Art, the Art Gallery of NSW Foundation, the Mercy Foundation and the Ted Noffs Foundation. He has shown himself to be a useful member of these groups, raising over $120 million for charitable purposes.
In 2007 Reg was made a Member of the Order of Australia for service to the visual arts as a supporter, patron and collector, and to the community through a range of social welfare and medical research organisations. In 2013 he was made an Honorary Fellow of the University of Sydney.
Professor John Thompson - AO MBBS BSc(Med) MD FRACS FACS
Professor John Thompson is both the Director of MIA and Professor of Melanoma and Surgical Oncology of The University of Sydney. He was appointed to the Board of Directors as a Non-Executive Director upon inception of the company in 2007. He is author of over 650 peer-reviewed articles and holds positions on the editorial boards of several international journals. Prof Thompson is a past President of the International Sentinel Node Society, and was Chairman of the Australian and New Zealand Melanoma Trials Group until 2014. He is also a member of the Melanoma Staging Committee of the American Joint Committee on Cancer, and chairing the Working Group to update the Clinical Practice Guidelines for the Management of Cutaneous Melanoma in Australia. Prof Thompson was made an Officer of the Order of Australia in 2014, “for distinguished service to medicine in the field of oncology research, particularly melanoma, to international and national professional organisations, and to medical education.”
Associate Professor Jonathan Stretch - AM D.Phil (Oxon) FRACS
Associate Professor Jon Stretch has been the Deputy Director of MIA since its evolution in 2007 from the Sydney Melanoma Unit. He was one of the founding Board of Directors at that time. A/Prof Stretch undertook his surgical training in Sydney becoming a Fellow of the Royal Australasian College of Surgeons (Plastic Surgery) in 1987. Thereafter he was Overseas Fellow at the Radcliffe Infirmary and Research Fellow in the Nuffield Department of Surgery, Oxford. His doctoral research investigated the local dissemination of melanoma. He was appointed to Royal North Shore Hospital in 1991 and the Sydney Melanoma Unit and Royal Prince Alfred Hospital in 2002. He is Associate Professor of Melanoma and Skin Oncology at The University of Sydney. He was made a Member of the Order of Australia in 2012.
Jennifer Elliott - BA, LLB (Hons), MA, FAICD
Jennifer Elliott was appointed as a Non-Executive Director of Melanoma Institute of Australia in 22nd of August 2012, and as Chair of the Finance Committee in 19th of March, 2013. Jennifer has broad Australian and international experience in the financial services industry, with a particular focus on business strategy, corporate governance and regulation, and human resources. She previously held various roles within Moody's Corporation for 20 years, including Regional Head - Asia Pacific for Moody's Investors Service, and Chief Human Resources Officer for the global Moody's Corporation. Prior to joining Moody's, Jennifer worked as a banking and finance lawyer in Sydney. She has degrees in English Literature and Law from Sydney University, and a Master in Asian Business Studies from SOAS at London University. In addition to her roles at the Institute, Jennifer is a Non-Executive Director of the Clarius Group and a Volunteer Ethics Teacher for Primary Ethics NSW.
Garry Sladden - BBus CPA FINSA
Garry was appointed as a Non-Executive Director of Melanoma Institute Australia in April 2011. Garry is a business and strategic adviser who has a diversified business background in the areas of real estate, private equity, business operations, banking and finance, and equity raising, having held the position of General Manager Operations at Consolidated Press Holdings for six years and more recently the role of Group Operations Executive for a real estate investment, development and funds management group. Garry is Non-Executive Chairman of Folkestone Limited, Ashton Manufacturing Pty Limited and Clarius Group.
Sally was appointed as a Non-Executive Director of Melanoma Institute Australia in March 2016. Sally co-founded the investment firm CP2 along with her late husband Peter Doherty and Professor Robert Officer in 1997. She held the position of Managing Director from 2012 to 2015, and has been Chair of the Board from 2007. Sally has 25 years’ experience in investment execution and managing investment portfolios for long-term investors. Through that time, Sally has helped navigate and keep CP2 focused despite difficult market conditions and the personal loss of her husband.
Professor Richard Kefford - AM MB BS PhD FRACP
Richard Kefford is Professor of Cancer Medicine at Macquarie and a Consultant Medical Oncologist at Westmead Hospital. He is Co-Director of Research at Melanoma Institute Australia (MIA) and an Honorary Professor in Medicine at the University of Sydney. He is Chief Investigator on NHMRC and CINSW Program Grants researching the molecular biology of melanoma, with particular focus on melanoma genomics and MAPK inhibitors. He has been an investigator on over 50 Phase I, II , III and adjuvant Clinical Trials in melanoma, including the recent development of targeted therapies and immunotherapy. He has authored over 340 peer-reviewed journal articles. He was Professor of Medicine at Westmead Hospital from 1998-2014. He has served as a member of the Australian NHMRC Academy, Research Committee, and Project and Program Research Committees and is a Member of the Ethics Committee of the Medical Oncology Group of Australia (MOGA) and the Board of the National Breast Cancer Foundation. He has served as a consultant to multiple biotechnology and pharmaceutical companies on melanoma drug development and clinical trials. He was awarded Member of the Order of Australia in 2009 for services to medicine in the area of oncology research, to professional organisations, and as an educator.
Professor Graham Mann - PhD
Professor Graham Mann is Research Director of the Melanoma Institute Australia, and co-Director of the Centre for Cancer Research, The Westmead Institute for Medical Research.
He leads a translational research program on melanoma with the support of NHMRC, Cancer Institute NSW and Cancer Council NSW. This program is engaged in all aspects of melanoma control, from the genetics of melanoma risk and its environmental and psychological aspects, to the use of molecular markers and targets to improve the diagnosis and treatment of melanoma.
He is Chair of the University of Sydney Cancer Research Network, a member of the Health Care Committee of NHMRC, and of the Scientific Steering Committee of the International Cancer Genome Consortium.
Professor Georgina Long - BSc PhD MBBS FRACP
Georgina Long is Professor of Melanoma Medical Oncology and Translational Research at The University of Sydney and Medical Oncologist at Melanoma Institute Australia. She leads an extensive clinical trials team and laboratory, with a focus on targeted therapies and immuno-oncology. She has also been the principal investigator on trials using anti-PD1 compounds as monotherapy treatment or in combination with other agents. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research, Georgina was awarded the Outstanding Cancer Research Fellow 2013 at the CINSW Premier’s Awards. She is a member of the Australian Melanoma Management Guidelines Committee, the ASCO Scientific Committee, and the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition. She is also on the editorial board of four journals.
Georgina was educated at The University of Sydney where she received her BSc (Hons 1) and was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Georgina became a Fellow of the Australasian College of Physicians in 2008, specialising in medical oncology.
Georgina is the author of more than 110 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and Cancer Discovery. Georgina has presented her work at international conferences and meetings on more than 100 occasions.
Professor Richard Scolyer - BMedSci, MBBS
Richard Scolyer studied medicine at the University of Tasmania (BMedSci, MBBS). After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Richard is currently Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney.
Richard has presented on more than 150 occasions at conferences throughout the world, and is a co-author of more than 300 articles and book chapters on melanocytic pathology and related research. In 2006, Richard was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier's Award for Outstanding Cancer Research in 2009 and 2012. He is also an editorial board member of the American Journal of Surgical Pathology, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. In 2013, Richard was appointed Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of their Cancer Staging System. He is currently President-Elect of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Richard is chief investigator on 5 year program grants from both the NHMRC and CINSW which were each renewed in 2010 and he also holds personal Fellowships from the NHMRC and CINSW.
Richard's wife Katie is also a pathologist and they have 3 children. In his spare time, he tries to keep fit, races his kids at swim club, barracks for the Sydney Swans and loves visiting the Tasmanian wilderness.
Associate Professor Robyn Saw - MBBS, FRACS, MS
Robyn Saw is an Associate Professor in Surgery at The University of Sydney. She is a Surgical Oncologist with MIA and also a General Surgeon at the Royal Prince Alfred Hospital. Robyn has a specific interest in the surgical management of melanoma and other skin cancers.
Research that can translate into clinical benefit for patients is the focus for her research activity. This includes a research interest in the development of lymphoedema (swelling of a limb) following lymph node surgery. As the Principal Investigator for a study looking at lymphoedema following axillary and groin sentinel node biopsy (supported by the NSW Cancer Council in 2005-2007 for 3 years for $180,000), the findings were presented at the 7th World Congress of Melanoma in Vienna 2009. A further paper has been published looking at lymphoedema following groin dissection in association with Prof Andrew Spillane.
A current project aims to establish an innovative stage III melanoma pre- and post-lymph node dissection clinic that combines physiotherapy, clinical nurse consultants and surgical consultants (with associated research opportunities to study patients preoperatively and postoperatively). This has the potential to improve the quality of care of all Stage III melanoma patients, and hopefully subsequently the quality of life of patients.
Currently, she is involved as Principal Investigator for an investigator led trial of “High Dose Vitamin D in High Risk Melanoma Patients” RPM Saw, B Armstrong, R Mason. R Morton (recruitment started Dec 2010). Involvement from the start with development of the trial protocol, and currently active in recruitment of patients, coordination of resources, supervision of trials staff, managing trial complications and advertising the trial has required commitment and significant time resources. This trial has generated significant international interest.
Intense involvement in the MIA BioSpecimen Bank and contributing patients for various clinical projects has also been on the agenda. She has also initiated banking of serial serum for all stage III melanoma patients in the future hope of development of serum biomarkers for assessment of prognosis and identifying early stage IV melanoma.
A range of students and junior medical staff have been supervised for research projects, including honours students for MBBS, interns interested in research and surgical trainees undertaking research projects as part of their Masters of Surgery research requirement.
Professor Gerald Fogarty - BSc, MBBS, FRANZCR
Professor Gerald Fogarty is the Director of the Mater Sydney Radiotherapy Centre. He is also on staff at St Vincent’s Hospital Sydney. He has spearheaded to use of Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy(VMAT) and Stereotactic Radiosurgery (SRS) and therapy (SBRT or SABR) , modern radiotherapy techniques, in those departments. The Mater Sydney is the nation leader in Volumetric Modulated Arc Therapy, an even more conformal means of delivering external beam radiotherapy safely, more rapidly and more economically. He trained at Peter MacCallum Cancer Institute, Australia’s largest cancer centre. He is a recognised authority in the radiation treatment of skin cancer. He has over 50 publications. He has NHMRC funding to over $1.2 million for an ongoing randomised trial of radiation in melanoma, He is also currently the Master of Warrane College, a university residence at University of NSW, Sydney.
Professor Helen Rizos - BSc (Hon) PhD
Professor Helen Rizos is a cancer cell biologist with an international reputation in the field of melanoma senescence, tumour suppressor proteins and oncoproteins. Her work combines genetic analyses of melanoma tumours with functional molecular and cell biology in order to understand the role and regulation of genes and cellular pathways that influence the development and therapeutic response of melanoma. Professor Rizos is an NHMRC Senior Research Fellow and recently moved to Macquarie University (January 2014) with her research team and Professor Kefford. Her research will continue to focus on melanoma cell biology and Macquarie University has all the required facilities and infrastructure.
Professor Andrew Spillane - MD FRACS BM BS
Andrew Spillane is Professor of Surgical Oncology at The University of Sydney, Northern Clinical School. He specialises in the surgical management of melanoma, breast cancer and soft tissue tumours. Andrew is currently a senior surgeon with MIA and a VMO at the Mater, Royal North Shore and North Shore Private Hospitals.
Andrew’s current research interests investigate issues around quality assurance in surgery, safe introduction of new surgical techniques and promoting clinical trial involvement by surgeons. He is involved in clinical and translational research on aspects of melanoma and breast cancer. He has authored 95 peer reviewed publications and co-authored 2 book chapters. Andrew is on the Executive of the Australian and New Zealand Melanoma Trials Group. He is President of Breast Surgeons Society of Australia and New Zealand Inc., a member of the Australian and New Zealand Breast Cancer Trials Group Locoregional Management Subcommittee and Chair of the Breast and Endocrine Surgical Group at the Mater Hospital. He lectures and teaches students at The University of Sydney’s, Northern Clinical School.
Associate Professor Pascale Guitera - FACD PhD
Pascale completed her dermatology training and fellowship at Hospital Saint-Louis in Paris. She was awarded the Australasian College of Dermatologist Fellowship in 2007. She completed a PhD in collaboration with the Curie Institute in Paris (one of Europe’s leading scientific institutions) and Royal Prince Alfred Hospital in Sydney. This work focused on novel imaging techniques for non-invasive diagnosis of skin tumours including in vivo reflectance confocal microscopy, high frequency ultrasound and multiphoton microscopy.
Pascale is a world expert in in vivo confocal microscopy and has been awarded the NSW Premier’s Award for outstanding research on lentigo maligna and confocal microscopy. Her areas of expertise are amelanotic melanoma, lentigo maligna and early diagnosis of melanoma in high risk individuals.
Pascale is Director of the Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital and the Dermatology Department at Melanoma Institute Australia. She is a senior researcher at The University of Sydney and supervises several PhD and Masters students.
Professor Peter Hersey - MBBS, FRACP, D.Phil (Oxon)
Professor Peter Hersey is a graduate of the University of Adelaide where he completed his clinical training as a physician. He completed his scientific training in the University of Oxford as a Nuffield Dominion Fellow in tumour Immunology. He has held positions as a Staff Specialist in Immunology in Sydney Hospital and the Calvary Mater hospital in Newcastle where he also held the positions of research director at the Newcastle melanoma unit and Conjoint professor of Oncology in the University of Newcastle. In 2010 he was appointed to the inaugural chair of Melanoma Biology in the University of Sydney and there has established a translational research laboratory working on melanoma in the Kolling Medical Research Institute based in the Royal North Shore Hospital. He continues his melanoma clinic in the Melanoma Institute of Australia and at the Lake Macquarie Private hospital in Newcastle.
Since taking up the staff specialist position in Sydney hospital he has carried out research on melanoma. The translational research activities have involved phase I-III trials in melanoma such as the conduct of a large phase III trial of immunotherapy in melanoma, use of modified peptide antigens and other melanoma vaccine initiative such as use of dendritic cell vaccines. He has taken a leading role in studies on properties of melanoma cells that make them resistant to treatment and new treatment approaches to overcome these properties. He is generally recognised as a pioneer of immunotherapy for melanoma in Australia and in focusing on properties of melanoma cells that make them resistant to therapies. He has held a number of consulting positions for pharmaceutical companies developing new treatments for melanoma and has held peer reviewed funding for melanoma research throughout his career. He has authored over 300 peer reviewed publications on melanoma and has been involved in conduct of over 50 clinical trials in melanoma.
Professor Angela Hong - MBBS MMed FRANZCR PhD
Professor Angela Hong is a Radiation Oncologist at MIA. She has been an active investigator on several radiation therapy trials with the aim to advance the treatment of melanoma. She is also a keen advocate in applying new technology in the management for advanced melanoma.
Professor Fran Boyle - AM MBBS (QLD) FRACP PhD
Professor Boyle is a Medical Oncologist at North Sydney’s Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She is involved in the oncology teaching program of the Sydney Medical School and in communication skills training through the Pam McLean Centre.
Professor Boyle's clinical practice at the Poche Centre focuses on breast cancer and melanoma. Her current research interests include clinical trials of new cancer treatments, psychosocial and supportive care, and communication. Fran Chairs the Board of Directors of the ANZ Breast Cancer Trials Group, and is a founding Director of the Australian Clinical Trials Alliance. She was honoured with Membership of the Order of Australia in 2008 for services to cancer research, advocacy, policy development and professional education.
Professor William McCarthy - AM
Professor McCarthy is Emeritus Professor of Surgery (Melanoma and Skin Oncology) at the University of Sydney. He was former Executive Director of the Sydney Melanoma Unit, and continues as a director of the Melanoma Foundation. A world leader in melanoma treatment and research, Professor McCarthy's contribution to the field was recognised in 1993 by Membership in the Order of Australia (Australia's highest community award).
Professor Omgo E. Nieweg - MD, PhD
Omgo E. Nieweg received his medical (1976) and Ph.D. (1983) degrees at the University of Groningen, the Netherlands. He undertook training in nuclear medicine and surgery at the University Hospital Groningen. He completed his surgical oncology fellowship at the MD Anderson Cancer Center in Houston, Texas in 1991. He was a staff member in the Department of Surgery, The Netherlands Cancer Institute in Amsterdam from 1992 to 2013. He joined the Melanoma Institute Australia in 2013 and was appointed to the Royal Prince Alfred Hospital, Sydney Day Surgery and The Mater Hospital in 2014. He is Professor at The University of Sydney.
Professor Diona Damian - PhD
Diona Damian is Professor of Dermatology at the University of Sydney, Clinical Academic at Sydney’s Royal Prince Alfred Hospital and Associate of the Melanoma Institute Australia. Her research focuses on the role of skin immunity and cellular energy in the causation, prevention and treatment of skin cancer. Current projects include skin cancer prevention and topical immunotherapy for recurrent melanoma.
Professor Nick Hayward - PhD
Nick is an NHMRC Senior Principal Research Fellow and Senior Scientist at QIMRB, where he heads the Oncogenomics Laboratory. After graduating with a PhD from the University of Queensland in 1983 he joined QIMR and has studied the molecular genetics of melanoma for 30 years. He is a foundation member of the International Melanoma Genetics Consortium (GenoMEL) and the Society for Melanoma Research. His work focuses on identifying high and low penetrance melanoma predisposition genes through linkage and genome-wide association studies, positional cloning and candidate gene analysis, as well as whole-genome and exome sequencing. Additionally, a large part of his research program involves identification and characterization of somatic mutations, structural aberrations, or gene expression differences associated with melanoma development and progression.
Dr Erin Mullan - BSc Md FRCPC FAAD FACD
Erin is a Canadian trained dermatologist who is also certified by the American Board of Dermatologists. She has also been invited to join the Australian College of Dermatologists after completing her fellowship at the Skin Hospital in Westmead. Erin is particularly interested in the management of skin cancers and dermatological surgery, but she also enjoys medical, paediatric and cosmetic dermatology.
Dr Kerwin Shannon
Dr Kerwin Shannon specialises in Head and Neck surgery and received his first clinical appointment to the Sydney Melanoma Unit in 1996. He subsequently undertook a 12-month Fellowship in Head and Neck Surgery at the University of Hong Kong, followed by a 2 year Fellowship in Head and Neck Oncology at the University of Tennessee, under the auspices of the American Head and Neck Society. Returning in mid 1999, Dr Shannon was appointed to the Department of Head and Neck Surgery of the Central Sydney Area Health Service and also resumed his association with the Sydney Melanoma Unit.
Research interests include organ preservation protocols, the use of regional chemotherapy for advanced head and neck cancers and sentinel node biopsy for melanoma of the head and neck.
Dr Kenneth Lee - MBBS FRACS
Dr Kenneth Lee is a graduate of The University of Sydney and completed his Plastic Surgery training in Adelaide. He undertook a Fellowship at the Canniesburn Hospital in Glasgow, Scotland specialising in Head and Neck Cancer Surgery and free flap reconstruction. Subsequently, he finished a clinical and research micro surgical Fellowship at the Eastern Virginia Medical School in the United States. He returned to Sydney and has been appointed as a Visiting Plastic Surgeon at the Royal Prince Alfred Hospital.
Kenneth’s interest is in the micro surgical composite tissue reconstruction for patients following trauma and tumour excision. His other interest is in the training of Plastic Surgeons for the RACS and has been a Supervisor in Plastic Surgery Training at the Royal Prince Alfred Hospital for over 20 years.
Kenneth joined MIA in 2012. He is at present the Supervisor for Plastic Surgery Training in Melanoma and Surgical Oncology at MIA.
Dr Sarah-Jane Schramm - PhD
Between January 2009 and July 2012 Sarah-Jane completed her PhD, titled 'Molecular biomarkers of melanoma progression and prognosis', under the supervision of Professor Graham Mann. Since that time, she has continued to work with the Melanoma Genomics Research Group, focussing on the burgeoning and multi-disciplinary field of cancer systems biology. Here, fields including statistics, molecular biology, genomics, pathology, and oncology are combined to discover and validate disease biomarkers that may have clinical utility. Since 2011, Sarah-Jane has co-authored more than nine research publications. She writes a monthly blog for the Sydney West Translational Cancer Research Center: The Inside Voice – reflections and ramblings of a newly minted post-doc.
Associate Professor Sydney Ch’ng - MBBS, PhD, FRACS
Dr Sydney Ch’ng was jointly appointed to the Departments of Plastic & Reconstructive Surgery, Head & Neck Surgery, and Surgical Oncology and Melanoma at the Royal Prince Alfred Hospital and Chris O’Brien Lifehouse Cancer Centre in 2013 upon her return from post-FRACS training overseas. She is also an Associate Professor at the University of Sydney.
Dr Ch’ng received her medical degree from the University of Melbourne. She undertook General Surgery training before specialising in Plastic and Reconstructive Surgery. During her training, she participated in the Surgeon Scientist Programme of the Royal Australasian College of Surgeons, and completed a PhD in the molecular biology of advanced skin cancers. Upon qualification as a Board certified Plastic & Reconstructive Surgeon, she undertook fellowship training in Head and Neck Surgical Oncology at the Royal Prince Alfred Hospital in 2011. Her further sub-specialty training took her overseas to Chang Gung Memorial Hospital, Taiwan for experience in adult facial trauma, and subsequently to Houston, Texas. She was a Microsurgery Fellow at M D Anderson Cancer Center from July 2012 – July 2013 as part of the American Society of Reconstructive Microsurgery fellowship programme.
Dr Matteo Carlino - BMedSc, MBBS, FRACP
Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals. He has recently completed a PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.
He continues to be involved in the translational research program based at the Melanoma Institute Australia and the Westmead Institute for Cancer Research. He is an investigator on multiple phase I,II and III clinical trials in melanoma targeted and immunotherapy.
Dr Alex Menzies - BSc(Med) MBBS (Hons) FRACP PhD
Dr Alex Menzies is a Medical Oncologist and Senior Research Fellow at Melanoma Institute Australia, Royal North Shore Hospital and The University of Sydney. He graduated with honours from the University of New South Wales in 2003 and completed specialist training in medical oncology in 2011. After completing a fellowship in clinical trials of melanoma, he received his PhD from The University of Sydney in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy. He is an investigator on Phase I to III clinical trials of targeted therapies and immunotherapies in melanoma, has published several original research and review articles, and is a regular invited speaker at national and international meetings. His main research interests are the biology of melanoma and biomarkers of response and resistance to systemic therapy. He has worked as a medical oncologist at MIA since 2012.
Dr Hsien Herbert Chan - BMedSci (Hons) MBBS (Hons) DPhil (Oxon) FACD
Hsien completed his medical training at the University of Western Australia in 2005. Following his junior doctor training at Sir Charles Gairdner Hospital in Perth, he received funding from the General Sir John Monash Foundation to complete a DPhil (PhD equivalent) in Immunology at the Weatherall Institute, University of Oxford, under the supervision of Professor Graham Ogg.
Hsien’s subsequent clinical training in dermatology was undertaken in New South Wales. His particular clinical interests include the early diagnosis and management of skin cancers and the management of inflammatory skin conditions. He is also a Visiting Research Fellow in Professor Wolfgang Weninger’s lab at the Centenary Institute, University of Sydney, where he focuses on the role of immune cell subsets in the pathogenesis of inflammatory skin disorders.
Associate Professor T. Michael Hughes - MBBS (Hons I) Sydney, FRACS
Associate Professor Michael Hughes graduated from the University of Sydney with First class honours in 1989. In 1996 Michael completed residency and advanced general surgical training at Westmead Hospital, Sydney. He was then appointed Clinical Supervisor in Surgery at Westmead and supervised surgical trainees across the Western Sydney Area. At the same time he developed his interest in Surgical Oncology, establishing a Melanoma and Surgical Oncology Service at Westmead with the guidance and support of Professor Rick Kefford. Michael also had the support and mentoring of Prof John Thompson, Prof Bill McCarthy and the team at the then Sydney Melanoma Unit(SMU) at Royal Prince Alfred Hospital. In 1998, Michael travelled to the Royal Marsden Hospital, London, to take up a Surgical Oncology Fellowship in the areas of Melanoma, Sarcoma and Breast Cancer. In mid 1999, Michael returned to the SMU as Lecturer. In 2000 he returned to Westmead to head up and further develop the Surgical Oncology Unit as well as working at the NSW Breast Cancer Institute. At that time Michael was also appointed as a consultant at the Sydney Adventist Hospital(SAH), Wahroonga, Sydney.
In 2010, Michael was appointed Associate Professor in Surgery at the newly established Sydney Adventist Hospital Clinical School, part of the Sydney University Medical School. As a consequence he left Westmead and works at SAH and Hornsby Hospital. Michael is now Head of General Surgery at SAH and chairs the Breast Cancer MDT with the planning of a melanoma MDT well under way. He continues to participate in the MIA MDT meetings on a regular basis. He looks forward to even stronger clinical and research links to MIA.
Leonie White - B APP SC (PHYSIO) MHIM
Leonie White is a physiotherapist with over 30 years experience in a wide range of settings including both public and private hospitals and private practice. In 1995 she completed training as a lymphoedema therapist and commenced working at Mt Wilga Lymphoedema Clinic gaining experience in all aspects of Complex Physical Therapy.
Leonie has over 17 years experience in lymphoedema treatment and regularly attends continuing education sessions and conferences in both Australia and overseas to update knowledge. In 2012 Leonie visited the world renowned Foeldi Klinik in Hinterzarten, Germany as well as the University Hospital in Montpellier, France to participate in further lymphedema training.
Leonie joined the PhysioOncology team at the Poche Centre in 2015. Her special areas of interest are improving patient outcomes by early intervention and the use of low level laser therapy for lymphoedema.
Dr Linda Martin - BSc(Med) MBBS(Hons) MMed FACD
Linda graduated in Medicine with first class Honours from the University of New South Wales in 2003. She undertook her dermatology training in Sydney and completed her fellowship at St John's Institute for Diseases of the Skin in London. Linda is also a Staff Specialist Paediatric Dermatologist at Sydney Children's Hospital.
Linda is interested in the early diagnosis of melanoma in high risk individuals and skin care while on targeted and immunotherapy for metastatic melanoma. Her research focuses on moles and melanoma in pregnancy. Linda is committed to educating patients about skin cancer prevention.
Michelle Avramidis - BSc
Michelle Avramidis is a professional medical photographer and research scientist. She has 18 years’ experience in total body photography and sequential dermoscopic imaging for melanocytic lesions. Her research focuses on dermoscopy for diagnosis of melanoma.
Dr Kim Isaacs - FRACS MBBS(Hons) BSc(Hons)
Dr Kim Isaacs is the 2016 Melanoma Institute of Australia Poche Fellow in Surgical Oncology. She a Fellow in General Surgery with the Royal Australasian College of Surgeons, and has sub-specialty interests in surgical oncology and rural surgery. She undertook general surgical training through the Prince of Wales Hospital network in NSW, and Southern Health Network in Victoria.
Dr Matthew Stodell - MBChB MRCS MSc
Matt is one of our 2016 Poche Fellows in Melanoma and Surgical Oncology. He is a plastic surgery registrar from the UK and is completing his higher specialty training in London. His subspecialty of interest is melanoma and skin cancer and he has taken 12 months out of his program to further his clinical and research experience by joining MIA.
Matt's research activities currently involve looking at imaging modalities for melanoma and the prognostic significance of sentinel node biopsy in comparison to the combined primary characteristics of melanoma.
Dr Louise Jackett - MBBS, BMedSci
Dr Louise Jackett is a fellow with MIA and is currently based in the department of Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital.
She graduated from medicine at the University of Tasmania with first class honours in 2007 and undertook training in Anatomical Pathology in Victoria at the Alfred Hospital and St Vincent’s Hospital. She obtained fellowship with the Royal College of Pathologists of Australasia in 2015.
Louise has recently commenced the Jani Haenke Melanoma Pathology Fellowship through MIA. In this position she is developing her skills in diagnostic melanoma pathology and hopes to contribute to the important work of the institute through new research activities.
Dr Michael Rtshiladze - FRACS(Plastic and Reconstructive Surgery), MS(Transplant Surgery), MBBS, BSc(med)
Michael is an MIA Poche Fellow for 2016. He is an Australian trained specialist plastic and reconstructive surgeon, gaining his qualifications in February 2016. Michael completed his advanced surgical training working across a number of major teaching hospitals in Sydney, including a 6 month appointment with MIA in 2014. He has a strong interest in surgical oncology, melanoma surgery and reconstructive surgery. His current focus with regards to melanoma research is the management of melanoma in-transit metastases and the emerging role of systemic therapies in their treatment.
Helen Schmid - RN, RM, DipAppSc, DipMgt, MPH
Helen has a background in general and midwifery nursing and a Masters in Public Health from the University of Sydney. She has previously worked in Boston and New York on HIV and AIDS clinical trials. She joined the melanoma research group at Westmead Millennium Institute for Medical Research in 1996 with Professor Graham Mann. Her main role is managing and coordinating the cancer genetic epidemiology projects for the Melanoma Research Program at Westmead and liaising with external and international research groups such as the GenoMEL consortium.
Dr Sarah Welsh - BSc PhD MBChB MRCP (Medical Oncology)
Dr Sarah Welsh is a post-doctoral fellow in Professor Helen Rizos’ research group. She is investigating the role of the immune system in determining response and resistance to melanoma therapy. She completed her PhD at The Institute of Cancer Research in London and a post-doctoral fellowship at Arizona Cancer Center in the USA prior to completing her undergraduate medical degree at The University of Oxford. She then trained as a Medical Oncologist at The University of Cambridge (Addenbrooke’s Hospital). She has authored publications in both clinical/translational and basic research and is a co-investigator on several clinical trials. She has also developed and patented 2 anti-cancer drugs, 1 of which has successfully completed Phase 1 clinical trials.
Chitra De Silva
Chitra has worked with Professor Peter Hersey for five years on the dendritic cell vaccine project. She then joined the melanoma biospecimen team collecting, processing & cryo-preserving specimens of melanoma tissue and blood, maintaining tumour bank database, overseeing quality control and record keeping while assisting with development of specimen collection protocols. She also participates as a member of the MIA research team to conduct clinical trials and major research programs. She has made major contributions to build up and maintain the Melanoma BioSpecimen bank and worked closely with research scientists and positively contributed towards several publications.
Gayathri St. George - Bmed.Sc, MSc.Med (RHHG)
Gayathri graduated with Bachelor of Medical Science and Master of Science in Medicine from The University of Sydney. She joined the Genetic Epidemiology group in 2007 and has been involved in various cancer genetic epidemiology projects for the Melanoma Program at Westmead. Her role entails data and sample collection, database management, obtaining biological samples, tumour banking, collating and updating epidemiologic, environmental risk factor, clinical and outcome information of study participants. She is currently completing her PhD with Professor Graham Mann looking at causes of early-onset non-melanoma skin cancers.
Mitchell Stark - BAppSc(hons)
Mitchell completed a BAppSc(hons) in 1998 and then joined the Oncogenomics Laboratory at the QIMR Berghofer Medical Research Institute (QIMRB) as a Senior Research Assistant and more recently as a PhD student (since Jan 2012). Over this time Mitchell has been investigating aspects of melanoma aetiology, including gene dysregulation during tumour progression along with predisposition in families with high risk of melanoma. Mitchell’s PhD research focus is identifying ‘melanoma-specific’ microRNAs that may be useful for clinical management of disease. Mitchell has extensive experience in the use of high-throughput genomic technologies, including microarrays to identify whole genome amplification and deletions in melanoma and next-generation sequencing for a variety of applications. The latter include small RNA (including miRNA) sequencing, CHiP sequencing to identify novel targets for transcription factors, along with whole-exome and genome sequencing to identify somatic mutations in melanoma as well as melanoma predisposition genes.
Caroline Watts - RN, RM, BA (Hons), MPH
Caroline works part time on genetic epidemiology of melanoma studies. She’s currently enrolled in a Doctor of Philosophy (Medicine) at Sydney University. Her research is examining if it is cost effective from both a NSW health system and societal perspective to manage individuals considered at high risk of melanoma in a specialised clinic. Supervisors are Dr Anne Cust, Professor Graham Mann, Professor Scott Menzies and Dr Rachael Morton.
Judith Symmons - RN
Judy is a research nurse who is responsible for coordinating the extraction, annotation and recording of patient information from state cancer registries and the National Death Index.
Dr James WIlmott - Bsc(Hons) PhD
Dr Wilmott has worked at the Melanoma Institute Australia since 2008, where he joined the Biospecimen Banking team. He went onto complete his PhD in 2013 which was entitled "Biology and biomarkers of BRAF mutant, BRAF inhibitor treated metastatic melanoma". He has published over 30 manuscripts which have been cited over 364 times, 245 citations were in 2013 alone (H-index 13). His research interests are biomarker studies of patients treated with targeted therapies and he is currently working as the project manager for the Australian Melanoma Genome Project.
Dr Lauren Aoude - PhD
Lauren completed Bachelor of Engineering and Bachelor of Arts degrees at the University of Queensland in 2004, after which she worked in the Drug Discovery and Oncogenomics laboratories at QIMRB before enrolling in a PhD in melanoma genetics through the University of Queensland, which she completed in 2014. Her research is primarily focused on discovering high-risk mutations in Queensland Families with melanoma. The project uses a next generation sequencing approach to sequence genomes and exomes of affected family members for candidate mutations potentially responsible for increased melanoma risk.
Varsha Tembe - PhD
Varsha works part time as a tissue bank officer and part time as a post doc on a translational project in a melanoma laboratory. Her tissue banking role involves collection and storage of tissues and bloods from patients seen in melanoma clinics at Westmead hospital. As a post doc she is investigating the use of circulating tumour DNA ( ctDNA) from plasma as a liquid biopsy.
Ms Suzanah Boyd has worked with Prof Rizos in melanoma research since 2007. She is highly skilled in mammalian cell culture and the functional analysis of oncogenic signalling pathways. Suzanah has contributed to six research publications since 2010, and is currently involved in the genetic analyses of melanoma tumours progressing on targeted therapies.
Dr Heidi Cameron - MBBS, FRACS
Heidi joined the QIMRB in March 2014 as a Masters of Philosophy student. Prior to this, she worked as a general surgeon. Heidi was awarded the MBBS from Monash University in 2004, then returned to Queensland, where she completed surgical training and was awarded a FRACS in February 2012. She then completed a BreastSurg ANZ Fellowship with an interest in melanoma surgery. Heidi’s research activities focus on assessing the feasibility of applying individualised treatment for patients based on the mutations detected in their resected metastatic tumour specimens, in an effort to begin to translate research advances to the clinic.
Dr Anne Cust - PhD, MPH(Hons), BSc, BA
Dr Anne Cust is an epidemiologist who conducts collaborative research aimed at identifying genetic and environmental causes of cancer, and improving cancer control and cancer outcomes. She is the recipient of fellowships from the NHMRC and the Cancer Institute NSW.
Libby Emmett - RN, Onc Cert, MMedSc
As a registered nurse with more than 20 years of experience working in oncology in Australia and the UK, Libby’s career has focussed on clinical trials. She has extensive experience working with patients in both the hospital setting and in the pharmaceutical industry. At MIA, Libby is responsible for developing and introducing new trials to the organisation, taking them from the feasibility stage to enrolment.
Ms Carina Fung has worked with Prof Rizos in melanoma research since 2009, and is highly skilled in molecular and cellular biology. Carina has contributed to six research publications since 2010, and is involved in the functional analyses of melanoma-associated tumour suppressor proteins and oncoproteins.
Dr Stuart Gallagher - PhD
Stuart is a cell biologist who has worked in melanoma research since 2004. He is working in Professor Hersey's laboratory investigating the emerging field of epigenetics, which studies how DNA is structured. His work is focusing on how epigenetics can be used to treat melanoma or make existing treatments more effective. He is an expert in melanoma cell culture, cell death mechanisms and oncogenic signalling pathways.
Maria Gonzalez - BN BA M.Hlth.Sc
Maria earned her combined Bachelor degrees in Nursing/Arts (English Literature and Gender Studies) and her Masters of Health Science from the University of Sydney. She has 10 years of clinical experience in surgical nursing but for the last 7 years has focused on clinical trial research nursing. During this time Maria has coordinated over thirty clinical trials predominantly in phase II and III research and has developed a particular interest in the management of investigator initiated protocols. In her current role as Clinical Trials Operations Manager, Maria leads a team of trial nurses and science graduates who are responsible for the coordination of surgical, medical and radiation clinical trials at the Poche Centre and Royal Prince Alfred Hospital. Maria joined the Institute in 2010 and is currently working on adjuvant systemic therapy trials investigating the use of targeted treatments following and preceding complete lymph node dissection.
Dr Kavitha Gowrishankar - PhD
Kavi (Kavitha) has worked with Professors Richard Kefford and Helen Rizos from 2009 till 2013 studying mechanisms of resistance to targeted therapy in melanoma, specifically BRAF inhibition. She is skilled in establishing primary cell lines from patient tumors and cell biological analyses of gene expression, including oncogenic signalling pathways. She is currently working with Prof Peter Hersey focussing on improving immunotherapy and is developing assays to study the impact of anti-melanoma drugs/antibodies on immune cells and function. She has contributed to nine scientific publications as part of MIA and her abstract on PD-L1 regulation in melanoma was selected recently for an oral presentation at AACR (2014). Her self described goal is to set up crucial pre-clinical models encompassing patient tumor cell lines, fibroblasts and immune cells, results of which can be extended to personalised medicine for melanoma.
Georgia Cairns - Dip App Sc. Nursing, MNurs, Grad Cert, Cert 4 Assessment and Training
Georgia has been a registered nurse since 1989.Working in multiple specialty areas across all phases of care (acute, rehabilitation and primary care) as an educator, specialist, consultant and manager. Georgia holds a Masters degree in Acute Care Nursing from The University of Technology, Sydney, graduating in 2005.
Georgia’s decision to join the Institute resulted from her interest in skin health and nursing people with an alteration to their health due to skin breakdown. Prior to joining The Melanoma Institute, Georgia was working as the owner/operator of a small wound care practice looking after patients with skin breakdown. In the last 5 years, Georgia worked as a nursing consultant in reconstructive plastic surgery and a medical device company with a product range associated with rapid wound healing. Georgia has previously worked as a health manager for an NGO, where she was involved in creating multiple educational resources for patients and has also been instrumental in designing multiple continence assessment tools and a booklet titled ‘solving common bowel problems for people with a spinal cord injury’ available on the CFA website.
Georgia was appointed to the role of Clinical Nurse Consultant at the Melanoma Institute Australia in November 2014.
Anna Hoadley - BA, MNurs, Grad Cert (Oncology)
Anna holds a Master of Nursing from Sydney University, graduating in 2007. Anna was appointed to the role of Clinical Nurse Consultant at the Melanoma Institute Australia in November 2013.
Anna holds a Graduate Certificate in Oncology Nursing and Australian Immunisation Certification.
Working in melanoma since 2009, she has experience in both medical and surgical oncology, complex wound and drain care, vascular access and chemotherapy.
Prior to her current role, Anna worked as the Ambulatory Care RN at the Royal Prince Alfred Hospital Melanoma Nursing Clinic for three years. Throughout 2013, she also worked as a Clinical Facilitator for Sydney University School of Nursing and Midwifery.
Anna’s earlier studies include a Bachelor of Arts from Auckland University in European languages, literature and music.
Lydia Visintin - R.N, MCaHaemN
Lydia is a highly experienced Registered Nurse and her career in cancer nursing began in 1990 at Royal Prince Alfred Hospital where she gained an enormous amount of expertise in Medical Oncology. In 2014 Lydia completed her Masters in Cancer and Haematology Nursing at the University of Sydney. During her time in Cancer Services, Lydia has gained extensive experience in both clinical and management roles.
Since 2004 Lydia has worked as a Clinical Nurse Consultant in melanoma providing support and expert nursing knowledge in the care of patients with advanced melanoma. She has comprehensive knowledge about targeted therapies and immune – oncology treatments for melanoma. Her role includes complex care coordination, support and education of patients attending various clinics, which include RPAH, The Chris O’Brien Lifehouse, Melanoma Institute Australia and Westmead Hospital.
Natalie Foster - BSc-Psy, BN
Natalie has worked at the Royal Prince Alfred Hospital in Sydney since 2007. During this time she has worked on a range of surgical wards, obtaining a valuable amount of surgical nursing experience which led to her working as a Clinical Nurse Specialist in Surgical Oncology.
In her current role as the Melanoma Clinical Nurse Consultant at the Royal Prince Alfred Hospital, Natalie provides expert clinical nursing support and education to both patients and their families whilst they are in hospital and then follows up on this care in the melanoma nursing clinic outpatient department. Natalie also coordinates the postoperative management of patients with complex wound and drain care by liaising with multiple community nursing services.
Natalie is currently undertaking further studies in a Masters of Cancer and Haematology Nursing at The University of Sydney and prior to commencing her nursing career completed a Bachelor of Science-Psychology at Macquarie University.
Melanie Doyle - RN
Melanie works in the Melanoma Nursing Clinic which includes assessment and management of complex wounds and drains, co-ordinating care with community nursing services, assisting in minor surgical procedures, providing education and support to patients and their family and carers. Prior to relocating to Sydney, Melanie was nursing at St Vincent's Hospital, Melbourne, gaining valuable experience in both acute surgical and medical nursing care.
Elizabeth Holland - BSc Macquarie University
Liz has worked with the Melanoma Genetics and Epidemiology Group and Professor Graham Mann since the early 1990’s. This group is part of a comprehensive research program focused on outcomes that will improve our understanding of melanoma and identify risk factors that will translate into better prevention strategies and treatments for patients. Liz's main role involves experimental design, database and biospecimen management, whole genome and exome sequencing, liaising with external and international research groups such as the GenoMEL consortium as a founding member.
Val started out as a registered nurse and then completed a Computer Science degree at The University of Sydney. Working in IT research at Westpac, Val gained a passion for research and completed a Masters of Commerce. Eight years ago, Val commenced working at MIA combining her passion for research and medicine, firstly in clinical trials working mainly on the MSLT-II surgical trial and then for the last 4 years as the BioSpecimen Bank Manager. Val manages a team of research staff across the Poche Centre and RPAH, and coordinates the consenting, collection and release of specimens (both blood and tissue) for research from patients seeing clinicians at MIA.
Ms Mal Irvine has worked with Prof Rizos in melanoma research since 2006. Mal brings significant technical expertise in mammalian cell culture and co-ordinates the Tissue Culture Facilities for our team. Mal has been involved in five recent research publications and is currently working on the therapeutic efficacy of ERK inhibitors in melanoma.
Dr Peter Johansson - PhD
Peter obtained his master's degree in 2001 and PhD in 2006 in Theoretical Physics at Lund University, Sweden. In his thesis he developed new algorithms for ‘omics’ data as well as used machine learning methods to dissect the molecular architecture of cancers such as melanoma and breast cancer. In 2007 he received an NCI Cancer Research Training Award and joined the Pediatric Oncology Branch at the National Cancer Institute within the National Institutes of Health, Bethesda, Maryland. Peter has spent more than 10 years writing scientific software and analysing biological data. He has extensive experience with building statistical models to distil large ‘omics’ data sets and identify variations of interest. In 2012 he joined the Oncogenomics Laboratory at QIMR Berghofer where he has set up an analysis pipeline for whole-genome and exome sequencing data as well as developed novel tools for identification of structural variants, DNA copy number aberrations and allelic imbalances.
Dr Teresa Lee - PhD
Dr Teresa Lee is a physiotherapist who specialises in lymphoedema and musculoskeletal problems related to cancer care. She attained a PhD in physiotherapy rehabilitation of breast cancer patients in 2008. She is a Research Associate at The University of Sydney. She started the Lymphoedema Clinic at the Sydney Melanoma Unit in 2008 and was the NSW representative for the Australasian Lymphology Association 2012 - 2014.
Her clinical interest includes the use of bioimpedance to assess limb extracellular fluid impedance ratios before and after surgery and/or radiotherapy. Her aim is to improve the management of patients at risk of, or who have, lymphoedema secondary to melanoma treatment. She has published in peer-reviewed journals and presented at oncology and physiotherapy conferences worldwide. She is an investigator in a number of Clinical Trials underway at the Melanoma Institute Australia.
Dr Elizabeth Liniker - MBBS B.Sc.
Elizabeth completed her medical training at the Royal Free and University College Medical School in 2007. She completed two years of medical oncology training at Addenbrooke's Hospital in Cambridge, UK prior to being appointed to the role of Medical Oncology Fellow at Melanoma Institute Australia in September 2014. She holds a Bachelor of Science in Tumour Biology.
Dr Serigne Lo - PhD
Dr Serigne Lo is a Senior Statistician and Senior Research Fellow in Biostatistics at the University of Sydney. He manages the R&BG and provides leadership in the conduct of cutting edge biostatistical methods and support across the institute. Prior to joining the MIA in February 2015, Dr Lo has accumulated 14 years of teaching/research experience including 8 years as biostatistician at the George Institute for Global Health – Australia.
Dr Lo has a strong background in quantitative analysis. He holds a Master in Econometrics (2002) and a PhD in Statistics/Econometrics from the University of Geneva (2006). He has worked across numerous disease areas and has been responsible for the design, the analysis and the reporting of health and medical studies for academic, drug regulatory agencies and government agencies. Dr Lo is interested in the development of new statistical methods. His personal research includes: Clinical trials, Adaptive design, Multistate modelling, and Joint-modelling.
Dr Lo is acting as Secretary on the MIA Research Committee, fielding project requests on the Melanoma Research Database (MRD), and is administering the review process.
Jim McBride - BSc
After graduating from Sydney University with a BSc in Computer Science, Jim’s career began in information technology roles in the petroleum then insurance sectors. His passion for how information technology can make a difference in the health sector took him to the Garvan Institute as their inaugural Information Technology Manager in 1995. He then moved in 2013 to MIA, taking the role of Information Technology Manager. Jim remains passionate about how information technology can make a huge difference in both direct patient care and in the longer-term benefits of research.
Dr Catriona McNeil - MBBS BSc(Med) PhD FRACP
Dr Catriona McNeil is an honours graduate of The University of Sydney. She undertook postgraduate medical training in Medical Oncology at Westmead Hospital, and later completed a PhD in molecular biology at the Garvan Institute of Medical Research. As a result of these studies she is a co-author of numerous scientific publications, and continues an active interest in Translational Cancer Research.
Dr McNeil is a Staff Specialist in Medical Oncology at the Chris O’Brien Lifehouse and Royal Prince Alfred Hospital where she has a clinical interest in the care of patients with melanoma and breast cancer. She is actively involved in the development and conduct of clinical trials of new agents targeting these malignancies, as well as in Phase 1 clinical trials across a range of malignancies.
Carol Morris - M Phty BSc Dip Sports Therapy
Carol Morris is a musculoskeletal physiotherapist who developed an interest in lymphoedema whilst working in the UK. After completing lymphoedema training in Austria, she continued treating patients both in the private and post-mastectomy hospital setting. Returning to Australia in 2007, Carol went on to complete her Masters of Physiotherapy. She also worked as a research assistant with the Breast Cancer Research Group at The University of Sydney and started working with Dr Teresa Lee at the Lymphoedema Clinic at Melanoma Institute Australia in 2012.
Carol's clinical interests include the effects of exercise and an active lifestyle on the affected limb after node removal surgeries and radiotherapy. Also working as a Sports Physiotherapist, Carol aims to provide patients with an integrated lymphoedema management approach to return patients to their pre-cancer activity levels.
Jane Palmer - RN
Jane is a research nurse with a career-long interest in melanoma who acts as the participant liaison. Her main role consists of recruiting participants, obtaining biological samples, and collating and updating genotype, epidemiologic, environmental risk factor, clinical and outcome information of study participants.
Svetlana Pianova - MSc
Svetlana has extensive experience in electron microscopy before she joined the Melanoma team at Westmead. Svetlana has worked with the Melanoma Genetics and Epidemiology Group and Professor Graham Mann since 2009. This group is part of a comprehensive research program focused on outcomes that will improve our understanding of melanoma and identify risk factors that will translate into better prevention strategies and treatments for patients. Svetlana's main role involves biospecimen management, biospecimen database management, whole genome and exome sequencing, DNA and RNA extractions for tumour and bloods and liasing with external researchers in genome projects.
Dr Antonia Pritchard - PhD, BMedSc
Antonia completed a BMedSc degree, followed by a PhD in genetics at Birmingham University, UK, before moving to Brisbane in 2005. Dr Pritchard's current research interests include tumour immunology and melanoma immunotherapy, in particular, the development of a new method to identify tumour specific vaccine and/or drug targets. Additionally, Dr Pritchard has continued her interest in genetics, to include familial susceptibility to melanoma, rare familial disorders and tumour genetics.
Dr Jazlyn Read
Jazlyn graduated with a Bachelor of Medicine/Bachelor of Surgery in 2013, after completing a Bachelor of Physiotherapy in 2009. Following more than a year of work as a part-time research assistant in the Oncogenomics Laboratory at QIMR Berghofer, she commenced study towards an MPhil in 2013. Her current project is investigating familial melanoma risk genes and links with other cancers.
Gullietta Pupo - PhD
Gulietta is part of the Melanoma Genetic and Epidemiology Group led by Professor Graham Mann. This group is part of a comprehensive research program focused on outcomes that will improve our understanding of melanoma and identify risk factors that will translate into better prevention strategies and treatments for patients.
Gulietta is involved in the genetic analyses of melanoma tumours progressing on targeted therapies, exploring biomarkers of response and resistance to targeted therapy, and exploring prognostic biomarkers in metastatic melanoma.
She has extensive experience with gene expression microarrays, DNA whole genome and exome sequencing, RNA sequencing, nanostring technologies and genome linkage analysis.
Freelance database developer since 1997 specialising in the FileMaker platform Database development on the Westmead campus since 1997. Ongoing development and support for the Cancer Genetic Epidemiology group, Storr Liver Unit, LECRR and Gynaecological Cancer.
Current clients at Westmead hospital include: Anaesthesia, Westmead Fertility, Gastroenterology and Dermatology departments.